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The Radboud Biobank offers disease-based biobanks a centralized facility to optimize the use and 
 distribution of biomaterial for scientific research. Notably, two population biobanks are also included 
in this collection. All collections are professionally and sustainably maintained using high-quality and 
secure standardized protocols for ICT, legal-ethical aspects, sample collection, processing and storage, 
 communication and distribution. The Radboud Biobank includes biomaterial (e.g. DNA, serum, plasma, 
 tissue, urine and faeces – depending on the specific patient group), images, associated clinical data 
(patient, disease-specific and phenotypic data) and derived information (genotypic data, microarray gene 
expressions). Patient  advocates and other relevant stakeholders are actively involved in the governance 
of the Radboud Biobank.
Keywords: Biobank; research-infrastructure; disease-based; biomaterial; clinical data
Funding statement: The Radboud Biobank was implemented by the Radboudumc Executive Board as part 
of the university research infrastructure. It is a central facility for the Radboudumc, with guaranteed 
central support for at least 15 years. A governing strategic board, encompassing relevant stakeholder 
groups, oversees the operations of the Radboud Biobank. Two patient representatives are included in this 
strategic board, and one holds the position of chairperson. 
(1) Bioresource Overview
Project description
The Radboud Biobank was established in 2012 with the 
aim of providing a centralized facility within the Radboud 
university medical center (Radboudumc) for the collection, 
storage and management of biomaterial, images and the 
corresponding clinical data. Its infrastructure is based 
on the Parelsnoer Institute model (PSI; [1]), which is a 
unique nationally representative biobanking partnership 
between the eight University Medical Centers (UMCs) in 
the Netherlands. It is expected that this infrastructure 
will serve as a conduit for generating robust scientific 
data, leading to improved health in patients as well as 
reinforcing the importance of biomedical research in the 
Radboudumc and abroad.
The Radboud Biobank was established to promote research 
for both prevalent and rare diseases (de novo biobanks, sec-
ondary use biobanks, remaining material from clinical trials 
and non-experimental follow-up  studies). Such studies may 
be initiated by the founders of the sub-collection. However, 
biomaterial and  clinical data from the Radboud Biobank are 
also available to other researchers with bona fide research 
protocols that directly or indirectly contribute to medical 
innovation. Each request for use of Radboud Biobank samples 
is reviewed by an institutional review board (IRB) and must be 
approved by the head of the sub-biobank.
The high requirements placed on quality, standardization 
and harmonization strengthen the research  possibilities 
and both quality and quantity of the scientific  output. 
Costs associated with patient inclusion and sample 
and data collection are covered by the participating 
 department. The Radboud Biobank covers the costs 
of sample preparation, freezing, storage and sample 
 management. For each issuance, investigators pay a fee 
to partly cover operational costs of the Radboud Biobank. 
The extent of the fee depends on the nature and quantity 
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Latitude: 51° 49′ 23.7324″.
Longitude: 5° 51′ 42.5046″.
Temporal coverage
Start data: January 2012. End date: not applicable (the 
intention is to include patients as long as possible, and thus 
there is no temporal limit); this implies that biomaterial and 
associated data will be stored without any time limitation. 
Temporal coverage for accessibility
N/A.
Radboud Biobank has not indicated a date for samples 
and data to be destroyed.
(2) Methods
Steps
Samples are collected in a routine clinical care setting. 
Individual clinical departments are responsible for this 
part of the biobanking process. Once a sample arrives at 
the Department of Laboratory Medicine, Human Genetics 
or Pathology, responsibility for the material is transferred 
to the Radboud Biobank. 
Sample handling and storage are based on standard 
operating procedures (SOPs). These procedures were 
established to ensure standardized sample collection and 
handling, and to guarantee a collection of samples of 
high and reproducible quality. Deviations from the SOPs 
are recorded as issues with haemolytic, lipemic, icteric, 
wrong tube, incorrect volume collected, deviation from 
time between sampling and storage, storage  temperature 
deviation, incorrect sample handling (centrifugation, 
mixing/homogenization) storage problem or other 
 deviation as free text. Figure 1 shows the schematic 
 workflow of the Radboud Biobank. 
Stabilization/preservation
Table 1 gives an overview of procedures for collecting, 
processing and storing of samples defined in the Radboud 
Biobank’s biomaterial protocol.




Shipping temperature from patient/source to 
preservation or research use
The Radboud Biobank is directly embedded in the routine 
processes of the Radboudumc.
• Body fluids (DNA, plasma, serum, urine, cerebrospinal 
fluid): Body fluids from the clinical departments are 
transferred by the internal clinical transport service, 
a pneumatic tube system, to the Radboud  Laboratory 
for Diagnostics (RLD). The RLD is responsible for the 
receipt of all samples. However, the sample handling 
takes place at the in-house Radboudumc expert 
 laboratories to ensure best practices in sample 
 handling. The samples for DNA-isolation are handled 
by Genome Diagnostics, Department of Human 
Genetics. All remaining samples are handled by the 
laboratory of Clinical Chemistry, Department of 
 Laboratory Medicine.
• Fresh frozen and Formalin-Fixed Paraffin-Embedded 
(FFPE) tissue: Fresh frozen and FFPE tissues are 
directly transferred from the operating rooms to 
the Department of Pathology by the internal clini-
cal transport service. The tissue should be sent in a 
good leak-proof, unadorned container with forma-
lin. The volume of formalin should be at least twice 
as large as the tissue fragment. Until transport, tis-
sue can best be stored at 4°C (refrigerator) or briefly 
at room temperature and not in (melting) ice.
Shipping temperature from storage to research use
Body fluids or materials and fresh frozen tissue samples 
are shipped on an excess of dry ice (–80°C) and FFPE 
 samples at room temperature. Shipment is carried out 
by various certified courier services. At the moment, data 
loggers are not used. However, each confirmation of 
receipt of a shipment attests that sufficient dry ice was 
still present in the package. 
Quality assurance measures
The sample handling is embedded in the quality 
 management system of all cooperating laboratories, i.e. 
Department of Laboratory Medicine, Human Genetics or 
Pathology. Process control is based on the department’s 
detailed SOPs.
Source of associated data 
The Radboud Biobank requires some basic data for the 
 catalogue, however, the department  responsible for a 
 specific disease-based biobank has defined a  minimal 
 dataset. This dataset comprises patient information 
 collected in the context of routine daily clinical  practice, 
among which are base-line data (patient history,  physical 
examination, diagnostic investigations, imaging, phar-
macy) and data obtained during the follow-up treatment 
of the patient. 
To facilitate follow-up, connections to existing 
 medical registries are actively sought. This includes, 
for example, links to registries for vital status, cause of 
death, hospitalization, cancer diagnoses and pathology 
records. 
Manders et al: The Radboud Biobank Art.2, p.  3 of 7 
The Radboud Biobank guarantees the privacy of the 
participants. Biomaterial and associated clinical data are 
stored using unique codes. The key connecting these 
codes to patient identifiers is kept by the owner of the 
specific disease-based biobank. The software package 
for the research database produces the unique code 
also noted on the application form accompanying the 
 biomaterial. The Radboud Biobank laboratory techni-
cian enters the same code in the laboratory sample man-
agement  software system. Each month, the Radboud 
Biobank  functional manager synchronizes the research 
 database and the sample management system using 
study  numbers. Pseudonymisation is mandatory since 
hospital patient identifiers do not adequately protect 
patient privacy. In situations of external use, Radboud 
Biobank identifiers are encrypted by a Trusted Third Party 
using TRES (Trusted Reversible Encryption Services).
Ethics Statement
All new biobank initiatives are assessed by the IRB. This 
board also evaluates each specific request for use of 
the biomaterial and accompanying data in subsequent 
research proposals. The IRB handles ethical assessment of 
biobank-related issues with consideration given to both 
quality (i.e. principles of Good Research Practice) and effi-
ciency (i.e. high frequency of meetings, digital procedure). 
A positive assessment is followed by an immediate 
 authoritative decision and fast delivery of the material to 
Figure 1: The flow of biomaterial and associated clinical data of a sub-biobank for the Radboud Biobank.
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the researcher. The head of a sub-biobank must also agree 
to the intended delivery.
In general, patients are asked to give broad consent. The 
biomaterial and associated clinical data that have been 
stored in the Radboud Biobank are released for research 
purposes only, after being approved by the IRB. 
Constraints
Geographical: the Radboud Biobank collects biomaterial 
primarily collected at the Radboudumc, a tertiary 
care hospital with a catchment area predominantly, 









The Radboud Biobank is the central biobanking  facility at 
the Radboudumc, Nijmegen, the Netherlands. The Radboud 
Biobank was implemented by the Radboudumc Executive 
Board as part of the university research  infrastructure. The 
Sample Volume/number Processing Time between 
sampling and storage
Aliquoting Storage
DNA (blood) 6 ml EDTA blood Standard DNA 
isolation from EDTA in 
clinical routine of the 
Department of Human 
Genetics









Serum 10 ml, addition of a 
clot activator 
2,000 × g at room 
temperature for 
10 minutes
Within 2–4 hours Maximum of six 
aliquots (0.5 ml)
−80°C2
EDTA plasma 10 ml 2,000 × g at room 
temperature for 
10 minutes
Within 2–4 hours Maximum of six 
aliquots (0.5 ml)
−80°C2
Heparin plasma 10 ml 2,000 × g at room 
temperature for 
10 minutes
Within 2–4 hours Maximum of six 
aliquots (0.5 ml)
−80°C2
Citrate plasma 9 ml 2,000 × g at room 
temperature for 
10 minutes




fluid (CSF) +/− cell 
count (CC)
3–20 ml 2,000 × g or 850 × 
g (CC) at 4°C or at 
room temperature 
(CC) for 10 minutes or 
5 minutes (CC)
Within 2 hours Maximum of six 
aliquots (0.5 ml)
−80°C2
Urine Not specified, 
midstream
2,000 × g at 4°C for 
10 minutes
Within 4 hours Maximum of six 
aliquots (0.9 ml)
−80°C2
Faeces Not specified Direct storage or after 
homogenization
Within 12 hours Maximum of six 
aliquots (5 gram)
−80°C2




after collecting the 
sample
Immediate 0.5 cm3 samples −80°C2




in formalin after 
collecting the sample 
(0.5 cm3), afterwards 
embedded in paraffin
Immediate fixation 0.5 cm3 samples Room 
temperature
Table 1: Overview of procedures on collection, processing and storage of samples defined in the Radboud Biobank 
biomaterial protocol. 
1 −20°C in a fully automated storage system.
2 −80°C in a manual storage system.
3 FFPE = Formalin-Fixed Paraffin-Embedded.
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Radboud Institute of Health Sciences (www.radboudumc.nl/
en/radboud-institute-for-health-sciences) hosts the Radboud 
Biobank as a separate entity, servicing all departments of the 
university medical center.
Radboud Biobank (830), Radboudumc, P.O. Box 9101, 
6500 HB Nijmegen, the Netherlands.
Bioresource contact 
Peggy Manders, Biobank Manager
radboudbiobank@radboudumc.nl







The Radboud Biobank is a hospital integrated biobank, 
i.e. all disease groups and clinical departments are repre-
sented. It stores all types of disease samples (see Table 1). 
Table 2 gives an overview of the disease categories that 
are included (as of July 2017). The Radboud Biobank 
catalogue provides real time information about the 
content of the Radboud Biobank.
A number of biobanks have recently received approval from 
the IRB and will start including data in the near future; these 
new biobanks include Hemangioma and congenital vascular 
malformations [7], Multiple Endocrine Neoplasia (MEN) [1], 
Pancreas cancer and pancreatitis [1], Esophagus and gastric 
cancer [1] and PTEN hamartoma tumor syndrome (PHTS).
Type of sampling 
The Radboud Biobank is a central biobanking facility for 
both common and rare diseases and comprises all types of 
collections, thus defined: 
−	 De novo biobanks: after careful appraisal of the  scientific 
ambitions and the consequences for the choice of spe-
cific patient categories, prospective inclusion of new 
patients with explicit consent to donate additional bio-
material and associated data, on top of that obtained for 
diagnostics, for future research purposes; 
−	 Secondary use biobanks: left over material obtained 
in the diagnostic or therapeutic process, for which 
the patients did not object to secondary use for 
 purposes of future research;
−	 Clinical trials and non-experimental follow-up studies: 
material of patients participating with full informed 
consent in studies with a specific research purpose; after 
completion of the trial, consent may be requested to 
keep the remaining material for future research.
Anatomical site 
The disease-based biobanks that are part of the Radboud 
Biobank (see Table 2) cover several anatomic sites of the 
human body.
Disease status of patients/source
See Table 2. 
Clinical characteristics of patients/source 
A full clinical characterisation, including patient history, 
physical examination, diagnostic investigations, imaging, 
pharmacy and follow-up is specified for each disease-
based biobank.
Vital state of patients/source
All patients are alive at inclusion.
Size of the bioresource
Currently, the Radboud Biobank has more than 350,000 
aliquots comprising different biomaterials (e.g. DNA, plasma, 
serum, urine, CSF, faeces and tissue) from over 32,000 
participants. The current number of unique patients 
included per disease-based biobank is shown in Table 2.
Clinical diagnosis of patients/source
The disease-based biobanks that are part of the Radboud 
Biobank (see Table 2) cover various clinical diagnoses.
Pathology diagnosis
The clinical diagnosis is registered using standard vocabulary 
(e.g. ICD-10 or SNOMED CT).
Control samples
The Radboud Biobank also has samples available from the 
general population (n = 6,737 – Nijmegen Biomedical 
Study [8] and n = 535 from the human functional genomics 
project [5]). The Nijmegen Biomedical Study [8] is a population- 
based survey conducted by the Department for Health 
Evidence and the Department of Laboratory Medicine at 
the Radboudumc. This population biobank consists of 
questionnaire data plus serum and DNA samples. The aim 
of the human functional genomics project is to characterise 
the interaction between the genetic background of the host 
and the consequences on an array of physiological functions 
and, in a subgroup of individuals, the cognitive function 
of the brain [5]. One section of the project investigates 
these relationships in healthy individuals (n = 535), while 
the second part of the project will assess the disturbance 
of this balance in specific cohorts of patients (see Table 2).
Biospecimen type 
Currently, a variety of biomaterials are stored in the 
Radboud Biobank. DNA is sampled and stored in almost 
all instances (96.6%), but the specific collection of other 
materials depends on the category of disease.
Release date
Biomaterial and the matching clinical data are currently 
available.
Access criteria
Biomaterial and clinical data from the Radboud Biobank are 
available to researchers worldwide. Each research application 
is reviewed by the IRB. Criteria used by the IRB for approval of 
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Disease-based biobanks Number of unique patients
July 2017 – n = 32,587 (%)
Confirmed form/increased risk of colorectal cancer1 494 (1.5)
Cerebrovascular infarct/cerebral haemorrhage/venous thrombosis1 733 (2.5)
Rheumatoid arthritis and arthrosis2 [2] 5,274 (16.2)
Neurodegenerative disorders (e.g. Alzheimer’s)1 124 (0.4)
Chronic (progressive) renal failure2 1,377 (4.2)
Crohn’s disease/ulcerative colitis1 382 (1.2)
Leukaemia, myeloma, lymphoma1 215 (0.7)
Type II diabetes1 400 (1.2)
Cerebrovascular vascular accident (18–50 years) 570 (1.7)
Ischaemic heart disease1 162 (0.5)
Anomalies in children (e.g. malformations of the kidneys and urinary tract, 
intestines and anus, lip and palate, and the heart, childhood cancers; [3])
4,592 (14.1)
Parkinson’s disease 1,230 (3.8)
Facioscapulohumeral muscular dystrophy (FSHD) 233 (0.7)
Infantile facioscapulohumeral muscular dystrophy (iFSHD) 45 (0.1)
Intellectual Disability 639 (2.0)
Breast Cancer 170 (0.5)
Asymptomatic women invited for breast cancer screening (50–75 years; [4]) 5,674 (17.4)
Immune responses and microbiome [5]
– Overweight patients (BMI>27)
– Recurrent Vulvovaginal Candidiasis
– HIV-infected patients







Cancer – breast, prostate, bladder, kidney, ovarian, melanoma, lung, testis 6,700 (20.7)
Autoinflammatory diseases 21 (0.1)
Familial bladder cancer 43 (0.1)
Myositis 30 (0.1)
Endocrine diseases 49 (0.2)
Urology 1,312 (4.0)
Hereditary prostate cancer 587 (1.8)
Congenital myopathy 9 (<0.1)
Gynaecological oncology 53 (0.2)
Systemic Sclerosis 222 (0.7)
Rhabdomyolyse 1 (<0.1)
Iron disorders [6] 11 (<0.1)
1 Parelsnoer Institute participant [1].
2 Both Parelsnoer Institute participant and department based biobank.
Table 2: Disease-based biobanks included in the Radboud Biobank.
applications are listed in Table 3. Access is open for investi-
gators from the department that initiated the diseased-based 
biobank and for investigators who seek cooperation with 
them. Cooperation with external researchers, including those 
working in the health industry, is encouraged.
After the IRB has approved the research application and 
the head of a sub-biobank also agrees to the intended 
delivery, the Radboud Biobank delivers the data and 
requested biomaterials to the researchers. Prior to the 
release, a standard Material (or Data) Transfer Agreement 
must be signed, which states that the biomaterial will not 
be used for other purposes than the original agreement, 
will not be delivered to third parties, remaining 
 biomaterial will be destroyed, and that feedback will be 
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1. Scientific and clinical relevance of the study.
2. Proposal that fits the original aim (and informed consent) of the collection.
3. Validity of the study design and proposed analyses.
4. Relevance of the requested material (type, volume, numbers) for this study.
5. Expertise of the applicant and the organisation for this study.
6. Appropriate measures for privacy protection.
Table 3: Criteria used by the institutional review board to review applications for the use of biobank material and the 
accompanying clinical data.
provided regarding the findings, profits and publications. 
Furthermore, new information that becomes available 
through scientific analyses will be added to the Radboud 
Biobank database. 
Researchers using the samples and clinical data pay a fee 
per sample, which is based on the nature and  quantity of the 
requested samples, and on the affiliation of the applicants. 
In addition, a fixed administrative fee is charged for each 
delivery. All revenues are used as return of investment.
(4) Reuse potential
Biomaterial and clinical data are provided to researchers 
on a non-exclusive basis, therefore samples from the same 
participant may be used in several different projects.
Any new research data generated by the delivered 
 biomaterial will be shared with the Radboud Biobank. This 
new information from scientific analyses will be added to 
the Radboud Biobank database to make it available for 
future non-commercial clinical, research and educational 
purposes.
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